View PDF of blog article here
A report by the Institute of Medicine is sharply critical of FDA’s drug safety monitoring system: "The report’s conclusions are striking and often damning – particularly when discussing the agency’s Center for Drug Evaluation and Research, known as C.D.E.R."
The $$$ amounts–one might call them, "fees for services rendered"–reveal the truth about who wields the greatest influence on NAMI policies–and whose interests are being served by NAMI.
AHRP proposes a multi-disciplinary team of independent scientists to review ALL of Dr. Joseph Biederman’s publications and supporting documents, including: research protocols, consent forms, and the original (of course, anonymized) data sets with associated code books for all pediatric studies.
Expert FDA Report: SSRI Suicide risk_SF Chronicle / NYT/ NJ Ledger/ AP Fri, 16 Apr 2004 FDA officials have provoked congressional hearings at which they will have to explain, not only why they concealed data linking antidepressants to increased violent and suicidal behavior, and why they covered up a report…
FDA Official Calls Newsletter Unethical – WP / Senate Considers Safety Reform at FDA – LAT Fri, 4 Mar 2005 The Washington Post reports about yet another instance of a high FDA official who misspoke. Dr. Sandra Kweder, Deputy Director of FDA’s Office of New Drugs, sent a letter, “written…
